KINIKSA PHARMACEUTICALS LTD's ticker is KNSA and the CUSIP is G5269C101. A total of 112 filers reported holding KINIKSA PHARMACEUTICALS LTD in Q4 2020. The put-call ratio across all filers is 0.66 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,952,900 | +74.8% | 170,000 | +41.7% | 0.04% | +50.0% |
| Q2 2023 | $1,689,600 | +20.8% | 120,000 | -7.7% | 0.03% | +7.1% |
| Q1 2023 | $1,398,800 | +33.4% | 130,000 | +85.7% | 0.03% | +75.0% |
| Q4 2022 | $1,048,600 | +35.8% | 70,000 | +16.7% | 0.02% | +60.0% |
| Q3 2022 | $772,000 | -34.2% | 60,000 | -50.5% | 0.01% | -37.5% |
| Q2 2022 | $1,173,000 | -57.2% | 121,184 | -56.0% | 0.02% | -52.9% |
| Q1 2022 | $2,739,000 | +53.9% | 275,623 | +82.2% | 0.03% | +70.0% |
| Q4 2021 | $1,780,000 | +101.6% | 151,265 | +95.2% | 0.02% | +100.0% |
| Q3 2021 | $883,000 | -12.1% | 77,500 | +7.6% | 0.01% | -16.7% |
| Q2 2021 | $1,004,000 | -64.9% | 72,000 | -53.3% | 0.01% | -80.6% |
| Q1 2021 | $2,859,000 | +169.7% | 154,340 | +157.2% | 0.06% | +158.3% |
| Q4 2020 | $1,060,000 | +1.7% | 60,000 | -11.8% | 0.02% | -4.0% |
| Q3 2020 | $1,042,000 | – | 68,000 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VHCP Management II, LLC | 639,230 | $11,091,000 | 3.32% |
| Boxer Capital, LLC | 1,172,700 | $20,346,000 | 2.30% |
| Sofinnova Investments, Inc. | 1,845,400 | $32,018,000 | 2.04% |
| Hillhouse Capital Management | 5,736,527 | $99,529,000 | 1.70% |
| Cormorant Asset Management, LP | 831,000 | $13,842,000 | 1.02% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1,226,890 | $21,287,000 | 0.75% |
| Foresite Capital Management IV, LLC | 94,477 | $1,639,000 | 0.56% |
| Vivo Capital, LLC | 186,073 | $3,228,000 | 0.42% |
| Baker Brothers Advisors | 3,000,000 | $52,050,000 | 0.39% |
| DC Investments Management, LLC | 30,817 | $535,000 | 0.34% |